CO - Global Cord Blood Corporation

NYSE - NYSE Delayed Price. Currency in USD
5.52
+0.08 (+1.47%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close5.44
Open5.48
Bid0.00 x 1000
Ask0.00 x 1300
Day's Range5.38 - 5.63
52 Week Range4.82 - 7.73
Volume38,526
Avg. Volume65,546
Market Cap670.962M
Beta (3Y Monthly)0.18
PE Ratio (TTM)18.84
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-07-31
1y Target EstN/A
Trade prices are not sourced from all markets
  • Bloomberg

    Hedge Fund Fights Over Stem-Cell Company's Value in Cayman Court

    (Bloomberg) -- A case brought by a U.S. hedge fund against China’s Global Cord Blood Corp. may set a precedent in the Cayman Islands for other minority shareholders who feel shortchanged by all-share mergers.Jayhawk Capital Management LLC and founder Kent McCarthy have sued the company and three of its directors, claiming a proposed $915 million all-share merger would reduce the value of their holdings. They are asking the Grand Court of the Cayman Islands to declare they can object to the deal, and have the right to ask the court to determine the fair value of their shares, an avenue currently only available in all-cash takeovers.The case is the first in which a minority stakeholder has attempted to get a Cayman court to determine the fair value it should receive in an all-share deal, said Tony Heaver-Wren, a partner at Appleby, the Cayman’s oldest law firm.Minority shareholders in cash-rich Global Cord Blood would end up with thinly traded shares with a lower value through the deal with Singapore-listed Cordlife Group Ltd., Jayhawk said in its complaint. Cordlife is partly owned by Global Cord Blood’s majority shareholder.The suit is also seeking to have the three directors removed from a special board committee assessing the offer, claiming they have received “generous compensation” from Global Cord Blood.Global Cord Blood, which is incorporated in the Cayman Islands and listed on the New York Stock Exchange, said it will “vigorously” defend the suit.“The company has reviewed the allegations contained in the summons and believes they are without merit,” Global Cord Blood said in a July 23 regulatory filing. The special committee is still evaluating the proposed merger, it added.The firm’s investor relations department declined to comment further.Global Cord Blood, once known as China Cord Blood, is China’s oldest and largest company that specializes in extracting, processing and storing umbilical cord stem cells that can be used to treat diseases such as leukemia.Shawnee, Kansas-based Jayhawk has been an investor for 12 years and holds an 11% stake.Global Cord Blood shares closed Friday at $5.42 in New York. The stock has fallen 16% this year.Jayhawk alleged a long history of corporate governance lapses at Global Cord Blood. The company twice issued convertible bonds in 2012, even though it didn’t need fresh capital, the hedge fund said in the suit.Minority shareholders were diluted by 50% after the bonds were converted into shares in 2017, in favor of then majority shareholder, Hong Kong-listed Golden Meditech Holdings Ltd., the suit says. Global Cord Blood’s board denied Jayhawk’s requests to buy the convertible bonds alongside Golden Meditech, the fund claimed.The three independent directors -- Mark Chen, Jennifer Weng and Ken Lu -- “have failed to exercise any independence or impartiality in approving the majority shareholders’ self-dealing transactions” in past decade, Jayhawk said in the suit.The trio allowed Golden Meditech to sell its 65% stake at about $11.70 each in January 2018 -- above the share price at the time without giving minority shareholders the same offer, the suit says.Global Cord Blood has accumulated $745 million cash while paying just one cash dividend since 2009, and the directors received restricted stock worth more than $1 million each and sold their holdings in 2017 when the stock price was at a peak, Jayhawk said.To contact the reporter on this story: Bei Hu in Hong Kong at bhu5@bloomberg.netTo contact the editors responsible for this story: Katrina Nicholas at knicholas2@bloomberg.net, Peter VercoeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 19-Jun-19 12:00pm GMT

    Q4 2019 Global Cord Blood Corp Earnings Call

  • China Cord Blood Corporation (CO) Q4 2019 Earnings Call Transcript
    Motley Fool

    China Cord Blood Corporation (CO) Q4 2019 Earnings Call Transcript

    CO earnings call for the period ending March 31, 2019.

  • Markit

    See what the IHS Markit Score report has to say about Global Cord Blood Corp.

    Global Cord Blood Corp NYSE:COView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CO. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $939,705 over the last one-month into ETFs that hold CO are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here’s What Hedge Funds Think About Global Cord Blood Corporation (CO)
    Insider Monkey

    Here’s What Hedge Funds Think About Global Cord Blood Corporation (CO)

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of December. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 26-Feb-19 1:00pm GMT

    Q3 2019 Global Cord Blood Corp Earnings Call

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 28-Nov-18 1:00pm GMT

    Q2 2019 Global Cord Blood Corp Earnings Call

  • Want To Invest In Global Cord Blood Corporation (NYSE:CO)? Here’s How It Performed Lately
    Simply Wall St.

    Want To Invest In Global Cord Blood Corporation (NYSE:CO)? Here’s How It Performed Lately

    After reading Global Cord Blood Corporation’s (NYSE:CO) latest earnings update (30 June 2018), I found it beneficial to look back at how the company has performed in the past and Read More...

  • Can Global Cord Blood Corporation (NYSE:CO) Improve Its Returns?
    Simply Wall St.

    Can Global Cord Blood Corporation (NYSE:CO) Improve Its Returns?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...

  • Disney shines, Yelp drops, Monster battles Coca-Cola
    Yahoo Finance

    Disney shines, Yelp drops, Monster battles Coca-Cola

    Disney, Yelp, Coca-Cola, Crocs and Facebook are the companies to watch.

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 24-Aug-18 12:00pm GMT

    Q1 2019 Global Cord Blood Corp Earnings Call

  • Should You Buy Global Cord Blood Corporation (NYSE:CO) For Its Dividend?
    Simply Wall St.

    Should You Buy Global Cord Blood Corporation (NYSE:CO) For Its Dividend?

    Dividends can be underrated but they form a large part of investment returns, playing an important role in compounding returns in the long run. In the past, Global Cord BloodRead More...

  • Iran's President warns of 'war situation' as US sanctions resume
    Yahoo Finance Video

    Iran's President warns of 'war situation' as US sanctions resume

    US unleashed 'toughest sanctions ever' on Iran. Yahoo Finance's Julie Hyman, Adam Shapiro, Andy Serwer and Campus Reform's Cabbot Phillips discuss with former US ambassador to Bahrain Adam Ereli.